Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 21, 2022 - Issue 11
Submit an article Journal homepage
868
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Immune checkpoint inhibitors-induced diabetes mellitus: a growing clinical presentation requiring our attention

Djordje S. Popovica Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Centre of Vojvodina, Novi Sad, Serbia;b Medical Faculty, University of Novi Sad, Novi Sad, SerbiaView further author information
,
Theocharis Koufakisc Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, GreeceORCID Iconhttps://orcid.org/0000-0002-5853-1352View further author information
ORCID Icon,
Bojan Kovacevicd Faculty of Medical Sciences, University of Kragujevac, Kragujevac, SerbiaView further author information
,
Manfredi Rizzoe Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), University of Palermo, Palermo, ItalyORCID Iconhttps://orcid.org/0000-0002-9549-8504View further author information
ORCID Icon &
Nikolaos Papanasf Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupoli, GreeceCorrespondence[email protected]
View further author information
Pages 1337-1339 | Received 21 Jul 2022, Accepted 06 Oct 2022, Published online: 11 Oct 2022

References

  • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
  • Abril-Rodriguez G, SnapShot: RA. Immune checkpoint inhibitors. Cancer Cell. 2017;31(6):848–848.e1.
  • Chang LS, Barroso-Sousa R, Tolaney SM, et al. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev. 2019;40(1):17–65.
  • Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–1768.
  • Matsuoka H, Hayashi T, Takigami K, et al. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody. BMC Cancer. 2020;20(1):656.
  • Paschou SA, Liontos M, Eleftherakis-Papaiakovou E, et al. Oncological patients with endocrine complications after immunotherapy with checkpoint inhibitors present longer progression-free and overall survival. Front Oncol. 2022;12:847917.
  • Zagouras A, Patil PD, Yogi-Morren D, et al. Cases from the immune-related adverse event tumor board: diagnosis and management of immune checkpoint blockade-induced diabetes. Oncologist. 2020;25(11):921–924.
  • Lu J, Yang J, Liang Y, et al. Incidence of immune checkpoint inhibitor-associated diabetes: a meta-analysis of randomized controlled studies. Front Pharmacol. 2019;10:1453.
  • Liu J, Zhou H, Zhang Y, et al. Reporting of immune checkpoint inhibitor therapy-associated diabetes, 2015-2019. Diabetes Care. 2020;43(7):e79–e80.
  • Chen X, Affinati AH, Lee Y, et al. Immune checkpoint inhibitors and risk of type 1 diabetes. Diabetes Care. 2022;45(5):1170–1176.
  • Wright JJ, Salem JE, Johnson DB, et al. Increased reporting of immune checkpoint inhibitor-associated diabetes. Diabetes Care. 2018;41(12):e150–e151.
  • Rui J, Deng S, Arazi A, et al. β cells that resist immunological attack develop during progression of autoimmune diabetes in NOD mice. Cell Metab. 2017;25(3):727–738.
  • Youssef N, Noureldein M, Daoud G, et al. Immune checkpoint inhibitors and diabetes: mechanisms and predictors. Diabetes Metab. 2021;47(3):101193.
  • Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021;17(7):389–399.
  • Zheng Z, Liu Y, Yang J, et al. Diabetes mellitus induced by immune checkpoint inhibitors. Diabetes Metab Res Rev. 2021;37(1):e3366.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.